Krishna Institute of Medical Sciences (KIMS) investor relations material

Executive summary

• Revenue grew 35.3% year-over-year in Q4 FY26 to INR 1,084 crore, with full-year consolidated revenue up 28.6% to ₹39,046 million.

• EBITDA margin declined to 19.9% in Q4 FY26 from 25.3% a year ago; full-year margin at 21.1% vs 26.6% last year.

• Net profit for FY26 was ₹2,420 million, down 41.7% year-over-year; EPS dropped 37.2% to INR 606.03/₹6.03.

• Bed capacity expanded to 6,464 in FY26, with operations across Telangana, Andhra Pradesh, Maharashtra, Kerala, and Karnataka.

• Expansion continued with new hospitals and activity centers in multiple states, and leadership maintained in organ transplantation and neurosciences.

Financial highlights

• Q4 EBIT was INR 216 crore, up 6.8% year-over-year; consolidated Q4 revenue from operations was INR 1,075 crore, up 34.8% year-over-year.

• FY26 EBITDA rose to ₹8,282 million, up 1.6% year-over-year; PAT margin dropped to 6.2%.

• ARPOB increased 14% year-over-year to ₹44,644 in FY26; ARPP rose 11.4% to ₹1,59,575.

• Occupancy rate remained stable at 50.5% in FY26 despite significant bed additions.

• Mature units contributed INR 862 crore revenue and INR 250 crore EBITDA in Q4, maintaining ~29% EBITDA margin.

Outlook and guidance

• Margin expansion expected as new units mature; EBITDA drag from new units to reduce by more than half next year.

• Adding 1,300+ beds through greenfield projects, acquisitions, and O&M opportunities to drive future growth.

• Focus on regional market leadership and strategic doctor partnerships to accelerate new business growth.

• Telangana cluster expected to see 10-12% EBITDA growth in FY27.